Recursion Pharmaceuticals, Inc.

$3.70- (-)1Y −37.52%

As of Oct 23, 2026 close

Market cap: $1.97B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $2.77$6.70
Volume (live): -
Avg. volume (3M): 29.01M

Recursion Pharmaceuticals, Inc. (RXRX) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Recursion Pharmaceuticals, Inc. stock.

Analyst Consensus Rating

Investment consensus from 8 professional research analysts

Consensus Rating

Hold

Based on 8 unique analysts

(12 total ratings in last 90 days)

Medium Confidence2.0:1 Buy/Sell

Average Price Target

$6.63

+79.19% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest RXRX Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 19, 2026	Gil Blum	Needham	Reiterates	Buy	$8.00
Oct 16, 2026	Alec Stranahan	BofA Securities	Maintains	Hold	$7.00 → $6.00 −1.00 (−14.3%)
Oct 16, 2026	Sean Laaman	Morgan Stanley	Reiterates	Hold	$5.30 → $5.90 +0.60 (+11.3%)
Oct 15, 2026	Edmund Ingham	Forbes	Initiates Coverage	Hold	-
Oct 12, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Sell	-
Sep 24, 2026	Ahan Chakraborty	Zacks Equity Research	Initiates Coverage	Hold	-
Sep 21, 2026	Alec Stranahan	BofA Securities	Maintains	Hold	-
Sep 15, 2026	Priyanka Grover	JP Morgan	Reiterates	Buy	-
Aug 17, 2026	Sean Laaman	Morgan Stanley	Reiterates	Hold	$5.50 → $5.30 −0.20 (−3.6%)
Aug 6, 2026	Brendan Smith	TD Cowen	Maintains	Hold	-
Aug 5, 2026	Brendan Smith	TD Cowen	Maintains	Hold	-
Aug 5, 2026	Gil Blum	Needham	Maintains	Buy	$8.00

Gil Blum

Needham

BuyReiterates

$8.00

Oct 19

Alec Stranahan

BofA Securities

HoldMaintains

$7.00 → $6.00

Oct 16

Sean Laaman

Morgan Stanley

HoldReiterates

$5.30 → $5.90

Oct 16

Edmund Ingham

Forbes

HoldInitiates Coverage

Oct 15

Zacks Equity Research

SellInitiates Coverage

Oct 12

Ahan Chakraborty

Zacks Equity Research

HoldInitiates Coverage

Sep 24

Alec Stranahan

BofA Securities

HoldMaintains

Sep 21

Priyanka Grover

JP Morgan

BuyReiterates

Sep 15

Sean Laaman

Morgan Stanley

HoldReiterates

$5.50 → $5.30

Aug 17

Brendan Smith

TD Cowen

HoldMaintains

Aug 6

Brendan Smith

TD Cowen

HoldMaintains

Aug 5

Gil Blum

Needham

BuyMaintains

$8.00

Aug 5

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 19, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for RXRX?

The analyst consensus rating for RXRX is Hold, based on the latest ratings from 8 analysts over the last 90 days.

What is the average price target for RXRX?

The average 12-month price target for RXRX is $6.63, representing an upside of 79.2% from the Oct 23, 2026 close of $3.70.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.